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Kyle of the University of California, Berkeley, facilitated the
workshop. This workshop involved several internationally
recognized dose-response modeling experts as well as LCIA
specialists (see footnote for the full list). The product of this
workshop is a set of short recommendations that are being
transmitted via this report.
Workshop Format
The workshop consisted of three elements:
(A)Presentations summarizing (1) the goals of the LCIA
Task Force (2) historical approaches to exposure and
toxic impacts in LCIA (3) current alternative proposals
for addressing human health impacts. Viewgraphs from
two of these presentations are provided in Appendix B
to this report.
(B) Discussion among a panel of experts about the scientific
defensibility of these historical and proposed approaches
in the context of the goals of the LCIA Task Force 3 on
toxicity impacts.
(C)Development of the recommendations to the LCIA pro-
gram and working group for optimum short- and long-
term strategies for addressing human health impacts
in LCA.
Background and Key References
Life cycle assessment (LCA) is a framework for comparing
products (or product-related emissions) according to their
total estimated environmental impact summed over all
chemical emissions and activities associated with the prod-
uct's life cycle. To assess human toxicity impact, the LCIA
practitioner considers for each chemical involved the cumu-
lative exposure associated with the mass released to a de-
fined (indoor, urban, regional, etc.) environment by multi-
plying the release amount by a measure of toxic impact to
characterize the likelihood of health effects and their poten-
tial consequences.
Introduction
The United Nations Environment Program (UNEP)/SETAC
Life Cycle Initiative aims at putting life cycle thinking into
practice and at improving the supporting tools for this proc-
ess through better data and indicators. The initiative has
thus launched three programs with associated working
groups (http://www.uneptie.org/pc/sustain/lcinitiative/). The
Task Force on Toxic Impacts was established under the Life
Cycle Impact Assessment (LCIA) program to establish rec-
ommended practice and guidance for use in human toxicity,
ecosystem toxicity, and related categories with direct effects
on human health and ecosystem health.
During the 2004 SETAC Europe meeting in Prague, an in-
ternational group of LCIA practitioners initiated activities
of the LCIA Task Force 3 (TF3) to address exposure and
toxicity with the goal of establishing guidance for LCIA. As
an adjunct activity of the 2004 SETAC World Congress in
Portland, Oregon, TF3 members organized a workshop to
review existing proposals on human toxicity indicators for
LCIA. The particular focus of this workshop was on options
regarding dose-effect response and severity. The review work-
shop consisted of formal presentations of approaches followed
by a review discussion performed by a panel of internation-
ally recognized dose-response modeling experts. This work-
shop was organized by Thomas McKone of the University of
California, Berkeley and Michael Hauschild and Stig Irving
Olsen from the Danish Technical University in Denmark. Amy
5 Besides the authors, other workshop participants were: Lois Swirsky Gold,
University of California, Berkeley, CA USA, Lorenz Rhomberg, Reviewer,
Gradient Corporation, Cambridge, MA USA, Glenn Suter, US Environ-
mental Protection Agency, Cincinnati, OH, USA, Jane Bare, US Environ-
mental Protection Agency, Thomas Gloria, Five Winds International,
Stefanie Hellweg, Swiss Federal Institute of Technology (ETH), Zürich,
Switzerland, Allan Astrup Jensen, Force Technology, Denmark, Randy
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The SETAC Life Cycle Impact Assessment (LCIA) Working
Group on Human Toxicity (Krewitt et al. 2002) have clas-
sified measures of toxic impact into two broad categories:
(1) potency-based characterization factors that are used to
assess the likelihood of a disease or effect (cancer, death,
reproductive failure, etc.) and (2) severity-based characteri-
zation factors or damage factors that, in addition to the
qualitative or quantitative likelihood of disease, reflect popu-
lation consequences of the disease in terms of years of life
loss or some other measure of societal impact. But rather
than indicating the likelihood of disease, potency mainly
indicates a dose that has an effect (the effect dose or ED) or
the lower confidence on the ED (Gold et al. 2003). Re-
cently, Crettaz et al. (2002) and Pennington et al. (2002)
have proposed for both cancer and non-cancer health im-
pacts in LCIA alternative approaches that include elements
of both the potency and severity impact measures note
above. For carcinogens, Crettaz et al. (2002) based their
approach on the maximum likelihood estimate of the dose
inducing a 10% response over background (the ED10) and
derive from this a linear low-dose extrapolation using the
slope 0.1/ED10. They obtain the ED10 values by using the
US EPA Integrated Risk Information System (IRIS), the
medium tumor dose rate (TD50) from the Cancer Potency
database of Gold et al. (2006), or data on median single
lethal dose (LD50). Potential consequences and severity are
addressed by combining the low-dose slope with a measure
of disability adjusted life years lost due to cancer to obtain
a aggregate number of disability adjusted life years (DALYs)
attributable to a specified chemical release. For non-car-
cinogens Pennington et al. (2002) follow an approach simi-
lar to that of Crettaz et al. (2002), but made use of the
benchmark dose to obtain a low-dose slope factor for non-
cancer diseases.
Review Questions
The workshop organizers provided a set of review questions
in advance to both the experts and other workshop partici-
pants. With regard to dose-response modeling in LCIA, the
workshop organizers structured these review questions into
five categories (Table 1): general issues, measures of potency,
species and population extrapolation, measures of severity,
and data quality and availability.
Workshop Findings
The workshop findings are organized into three catego-
ries – overarching issues, measures of potency, and meas-
ures of severity.
1. General issues 
 What is the scientific evidence for classifying any substance as a human carcinogen? 
 What is the scientific evidence for classifying any substance as inducing some type of non-cancer disease impact such as neurotoxicity, 
reproductive toxicity, respiratory irritation, developmental delay, asthma, autoimmune diseases, etc.? 
 What is the validity and utility of using non-threshold linear dose-response models for assessing either cancer or non-cancer population disease 
burden?  
 Are disability adjusted life years (DALYs) an appropriate endpoint measure of disease burden for life-cycle impact? 
 Are there alternatives to DALYs that should be considered? 
 Should we consider individual or population (collective) risk as a measure of impact in life-cycle assessment? 
 When combining the effects from exposures to multiple harmful substances, should we consider effect additivity, risk additivity, or cumulative 
disease burden in a measure of human health impact for LCA? 
2. Measures of potency 
 What is the basis for the potency measure (e.g. critical effect, most severe effect, etc.)? 
 Should carcinogens and non-carcinogens be separated when calculating health impact midpoints and/or health impact endpoints? 
 For non-cancer outcomes should the midpoint and/or endpoint measure of disease burden make use of no adverse/lowest adverse effect 
(NOAEL/LOAEL) doses or benchmark doses (e.g. TD50, ED10)?  
 For cancer outcomes should the midpoint and/or endpoint be based on slope factors or other potency measures such as benchmark dose? 
3. Species and population extrapolation 
 In developing dose-response and disease burden models, should we apply extrapolation factors to account for differences between animals and 
humans, between sensitive subpopulations, etc.? 
 If we use extrapolation factors, how should the extrapolation factors be derived, e.g. probabilistic methods or some set of default assumptions? 
4. Measures of severity 
 Should and how can LCIA models of toxicity include the severity of the effect? 
 Should severity assessment be qualitative (indicator-based), semi-quantitative, or quantitative? 
 If the measure of severity is quantitative: should the model include full damage modeling, that is both morbidity and mortality, and how should 
mortality and morbidity be aggregated? 
 Should the model include partial damage modeling (e.g. only mortality)?  
 What methods of damage modeling should be used? 
 If the measure of severity is semi-quantitative or qualitative, what approach should be used to categorize and/or classify severity?  
5. Data quality and availability 
 Can and how should data quality for human health impact and disease burden be quality assured?  
 Are both experimental data and derived 'safe' levels such as allowable daily intake (ADI) and reference dose (RfD) from the EPA IRIS database 
etc. available for a broad set of chemicals?  
 What is the minimum level of data availability required to establish the lethal dose for 50% of a population (LD50), NOAEL, and/or benchmark 
doses from chronic studies?  
Table 1: Questions addressed by the review workshop
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Overarching Issues
In concurrence with other workshop participants, the dose-
response experts concluded that it is appropriate to include
human toxicity in the LCIA process. The basis for this rec-
ommendation is that, in the absence of a toxicity metric,
many LCIA practitioners will continue to rely on emissions
magnitude as a measure of emissions impact. But, because
of the significant differences among chemicals in the dose
levels that are toxic, it is essential to consider human toxic-
ity in comparing releases of different toxic chemicals.
There is an overarching concern that the LCIA process should
address toxicity but limit the level of detail in the analysis to
information that provides benefits or value to the overall
LCIA. Too much detail can reduce the transparency and re-
liability of the LCIA. However, there may be cases where
more analysis matters. That is, cases where exposure is be-
low a threshold of effect and for which more details on the
distribution of population exposure will impact estimates
of disease burden.
Measures of Potency
The expert panel recommended the use of a hierarchy of
toxicity values in LCIA with priorities assigned so that LCIA
assessors can evaluate the relative advantages of different
toxicity metrics. The goal is to allow LCIA assessors to de-
termine which metrics would be scientifically defensible and
informative as well as identifying methods that are trans-
parent and easy to use. With regard to measures of potency,
the workshop participants made the following specific rec-
ommendations.
a) Human preference: Relevant and applicable human
data should be given priority wherever such data are
available.
b) Preference for benchmark measures: The review panel
preferred the use of benchmark measures of effect as a
means of scaling relative toxicity, rather than a no ob-
served adverse effect level (NOAEL), lowest observed
adverse effect level (LOAEL) or Reference Dose (RfD),
which is derived from NOAEL or LOAEL. Benchmark
measures include the ED10, the dose that results in a
toxic effect to 10% of the exposed population, and the
ED50, the dose that results in a toxic effect to 50% of
the exposed population. The basis for this recommenda-
tion is the frequent dependence of the NOAEL or LOAEL
on the limitations of study design. However, the experts
expressed the view that it would be better to use the
NOAEL or LOAEL rather than no measure at all, as a
basis to estimate ED10 or ED50. Given the overall un-
certainties, there are large differences between these al-
ternate approaches in ranking chemicals in LCIA. RfD
values are obtained from NOAELs or LOAELs using
safety or uncertainty factors that reflect differing degrees
of precaution or protection. As a result, it is not clear
whether the RfD, which was developed to provide an
adequate margin of safety, can provide the consistent
measure of harm needed in LCIA. Thus, when an RfD is
used in chemical ranking, the panel recommended that
the uncertainty measures used and the corresponding
NOAEL or LOEL should be separated out from the RfD
and reported along with the RfD.
As a follow-up issue, the panel identified the need to
come to a conclusion about whether an ED10 value, an
ED50 value, some other benchmark (ED25), or some
approach that combines these benchmark doses would
be best suited to LCIA. The ED50 is at the median of the
range of doses that produce significant results. The ad-
vantages of the ED50 are that it is a more stable meas-
ure and represents the point most comparable among
biological species. The ED10 is usually within the dose
range tested for statistically significant results. The ad-
vantage of the ED10 is that the information about slope
or dose-response that is most chemical specific is be-
tween the ED50 and ED10 range, and this is better cap-
tured in the ED10. But the use of ED10 will not auto-
matically reduce the level of uncertainty for low dose
extrapolation. If a practitioner believes that 'slope' val-
ues from animal studies predict human values, this would
argue for using the ED10. But this is a question that
requires further research and for which we do not yet
know the answer.
A related need is to determine how to make use of com-
binations of ED50 and ED10 and possibly LOAEL and
NOAEL in life-cycle impact rankings. The experts rec-
ognized that when these different measures are combined
there is a need for correction factors to make them con-
sistent, to correct for data from different species, and to
correct for differences in duration of the experimental
exposures. The correction factors should be used to steer
all values to best estimates as opposed to the most health
protective values. It is important to avoid introducing
bias even with methods that are consistent. There is a
need to include a larger number of chemicals in studies
of correlation among the different measures of toxicity
that were discussed at the workshop.
c) Complexity of multi-chemical comparison and low dose
extrapolation: The complexities of the analysis make it
somewhat difficult to understand how the various dose-
response methods might compare with respect to the
value of information they provide to an LCIA. This prob-
lem derives in large part from differences among the
methods of low dose extrapolation. LCIA involves com-
parisons among the life cycles of products not compari-
sons among the life cycle of chemicals. But even though
this leads to comparisons among chemicals, LCIA is
more complicated than single chemical comparisons.
Moreover, the problem is one of multi-dimensional op-
timization. This means that one input depends on oth-
ers. In LCIA we need a way to compare processes and
activities that are not always comparable. The need to
confront and inform tradeoffs requires the ability to ex-
press relative preferences.
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d) Normalization: Normalization is a critical issue. It is im-
portant to determine what to use as normalizing factor.
There are differences between normalizing to manmade
changes and to natural background. Global warming
provides a cautionary example. The discussion of the
relative importance of environmental exposure as a cause
of human health impacts and hence the relevance to ad-
dress human toxic impacts in life cycle impact assess-
ment lead to identification of a need for normalization
against other types of impact.
Measures of Severity
With regard to measures of severity, the workshop partici-
pants made the following specific recommendations.
a) Relation between severity and potency: The expert panel
noted the value of taking severity into account but hesi-
tated to recommend specific methods to characterize se-
verity. They took this position because the way that po-
tency is addressed will bear on severity but is not yet
fully decided in the LCIA literature. In other words, it is
necessary and acceptable to address severity, but we need
to work out the specifics of potency issues to decide how.
The panel recognized that not using some measure of
severity is the same as treating all outcomes as having
equal severity. When confronting severity, there may be
some simple methods that are more applicable in some
cases, such as distinguishing between carcinogens and
non-carcinogens, but, such approaches will also mask
real differences in some or many cases. On the other hand,
the panel expressed concern that explicitly treating se-
verity may imply that we know more than we do and
that we can estimate severity better than is actually fea-
sible. We want to avoid this situation.
b) Multiple effects: It may be appropriate to look at more
than one outcome. Similar to other approaches, the RfD
approach looks for the critical effect, which is the one
that may occur at the lowest dose. The panel noted that
this involves toxicity testing that is carried out to find
the lowest level that produces an effect rather than com-
pleting a whole battery of tests at higher doses. This is
appropriate when looking for a 'safe' dose but may not
be appropriate when trying to characterize representa-
tive impacts or the DALY burden on a population. More
severe or more common outcomes that are not the ones
that occur at the lowest dose may also be important.
With only critical effects testing it is not possible to ob-
tain information on more severe outcomes that occur at
higher doses. It may be very important to include a very
common but not very severe outcome or a rare but very
severe outcome. Thus, there is a need to develop meth-
ods to address these concerns.
c) Aggregation: There are aspects of toxic impacts that
should be aggregated and other aspects that should be
kept disaggregated. There could be elements of severity
that fit both. In contrast to policy assessors, modeling/
methods experts may have different needs in regard to
the issue of aggregation.
If we are going to put a valuation on an endpoint, it is
important to be transparent. The experts expressed con-
cerns about DALYs because they represent one judgment
about the significance of various health outcomes but
these judgments may not be those of the target audience
and may not have an established empirical basis. Thus,
along with DALYs the analyst should report separately
intermediate results such as Years of Life Lost (YOL) or
years of life disabled. Additional weighting coefficients
should be reported in a transparent way.
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ILSII panel 95: Limitations of RfD
for an application to LCIA
Burke et al., 1996 (ILSII panel) recommended to use the
NOAEL or response doses rather than RfD,
since the comparison of toxic releases based on their RfD
can be biased, because:
•  The UFs applied to derive the RfD are conservative.
• The response level associated with the No Observable
Adverse Effect Level (NOAEL) can change.
• The RfD is dependent on the experimental design.
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a g g r e g a t i o n  o f  
d i f f e r e n t  m o r t a l i t y  
e f f e c t s   
G i v i n g  t h e  s a m e  
v a l u e  t o  a n y  l i f e  
y e a r : a  v a l u e  c h o i c e   
n o t  c o v e r  n o n - f a t a l  
e f f e c t s .  
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a p p l i c a t i o n s  
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A stepwise procedure (SETAC-EU WGIA2)
1. Toxicological potency indicators such as ED10
as a minimum default
- While methods in their infancy, it is encouraged
to take into account relative severity,
--> 2. YOLL 3. DALY/QALY
Key tasks:
- Lack of toxicity data
- Population density
- Aggregation linked to severity authorised by
international body
6




Points to be adressed
- How to derive dose-response information for a
large number of chemicals (eventually screening
and advanced approaches) ?
- Relevance: How to relate the animal endpoint to
human endpoints and eventually YLL, YLD ?




Points to be raised
- Extrapolations chemical with acute, QSAR: shows that
restricted !!
- Severity: as soon as impact scores are added, a
weighting is performes with equal severity. If all
endpoints are kept separate  OK
- Interesting to come to DALY because: upper limit, put
into perpective to observed damages
- Always come back to initial goal of comparison  kg
equ substance to communicate
- The way it can be used in practice: BMW
7
















































XX               Values observed in a bioassay
-----           Maximum likelihood estimate












Linearity at low doses ?
Below 10% effect, the answer depends only on
the model retained ! Impossible to predict
(non-) linearity on the basis of bioassays !
Figure 2.6 Effect doses ED10h and ED0.001h, calculated for acephate using different





















the tumor dose TD50a
• The TD50s - ED10s correlation is relatively high  (n=37; R 2=0.75) 
• Apply to 671 substances with a TD50a in the CPDB [Gold and Zeiger, 1997]
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log(ED10h)

















Correlation ED10 - TD50
data provided for 670 carcinogens
ED10h  =  TD50a/22 ; R2=0.94
Dose-response: 80% variation between databases, against 


























 a n d  ! E D 1 0  a r e  s t r o n g l y  c o r r e l a t e d  ( R
2
 =  0 . 9 4 ) :  
q 1 *  r e f l e c t s  a  l i n e a r  a s s u m p t i o n  ! !  
 
 
O n  a v e r a g e ,  q 1
*  












0 1 2 3 4 5
log(LD50a)
log(ED10h)
ED10h = 0.042 * LD50a
0.52 
The LD50s - ED10s correlation is rejected (n=41; R2=0.14)
==> No assessment of data-poor substances is provided!
10

























































































(n = 6; R2 = 0.98)
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n = 9, R2 = 0.99
12

























































































Dockery et al. (1993) Pope et al. (1995)
Pope et al. (2002) Kuenzli (Dockery et al. 1993 and Pope et al. 1995)
EPFL (Dockery et al. 1993 and Pope 2002 et al. 2002)
 
Main epidemiological studies: chronic mortality
14









































































































































































































































Carcinogenic effects (lung cancer)







































































































































































PM10 PM2.5 PM(tot) Diesel Exhaust
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Severity of the endpoints





















Reversible / notMay be irreversible/
         3          2
[Burke et al, 1996]
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Disability Death Disability + Death 
Type of Cancer W 
[ - ] 
D 
[yr. lost/inc.] 






YLLp = L/N 
[yr. lost/inc.] 
DALYp = YLDp + YLLp 
[yr. lost/inc.] 
Mouth and oropharynx 0.145 4.3 0.62 3.2E+06 1.1E+06 2.9 3.5 
Oesophagus 0.217 1.7 0.37 3.4E+06 3.8E+05 8.9 9.3 
Stomach 0.217 2.9 0.63 7.0E+06 1.1E+06 6.5 7.2 
Colon and rectum 0.217 3.7 0.80 3.9E+06 9.9E+05 3.9 4.7 
Liver 0.239 1.6 0.38 6.3E+06 5.4E+05 11.6 12.0 
Pancreas 0.301 1.2 0.37 1.5E+06 1.9E+05 7.9 8.3 
Trachea, bronchus, lung 0.146 1.8 0.26 8.3E+06 1.1E+06 7.9 8.2 
Melanoma 0.045 4.2 0.19 5.1E+05 1.7E+05 3.1 3.2 
Breast 0.069 4.2 0.29 3.8E+06 1.1E+06 3.6 3.9 
Cervix uteri 0.066 3.8 0.25 2.7E+06 4.5E+05 6.0 6.2 
Corpus uteri 0.066 4.5 0.30 5.8E+05 3.1E+05 1.9 2.2 
Ovary 0.081 3.4 0.28 1.3E+06 2.0E+05 6.4 6.7 
Prostate 0.113 4.2 0.47 1.1E+06 6.8E+05 1.6 2.1 
Bladder 0.085 4.2 0.36 9.8E+05 4.6E+05 2.1 2.5 
Lymphomas and myeloma 0.089 3.5 0.31 3.0E+06 4.2E+05 7.2 7.5 
Leukemia 0.112 3.1 0.35 4.4E+06 3.1E+05 14.3 14.6 
Other cancers* 0.809 n.a.  1.3E+07 1.0E+06 13.0 13.0 
Average       6.7 
 Due to difficulty to determine human endpoint,





- Dose-response for animal  human endpoints
- No severity = (Implicit) weighting in LCA,
 when summing up accross substances
assume equal severity !! Not ISO compatible
- Report death, N°cases, YLL, YLD separately
- Disability weight optionals, new approaches to
establish them
17







- Stay at separate endpoints for animals (Owens)
- Endpoint animals = endpoint humans ? No !
- Start from human evidences and link it back to
or use animal dose-response.
a) If similar endpoints human-animals =
lower uncertainty
b) If different endpoints human-animals =





Strong humans YLL/incidence Duration Disability YLD    DALY
evidences   years  years weight
Cirrhosis   17  7.8 0.33     2.6   19.6
Hepatitis  2.14  0.17 0.20     0.04   2.18
Appendix B: Dose Response Workshop
L. Rhomberg Presentation
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Risk must be a linear function of Exposure
(in the range of interest)
! 








Appendix B: Dose Response Workshop
L. Rhomberg Presentation
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Source:  US EPA, 1995.  The use of the benchmark dose approach in health risk assessment.  Risk Assessment
Forum,

























 Threshold effects; nonlinear dose-
response
 Traditional approach focuses on
identifying a dose-rate likely to be
"safe" (and not on dose-response)
Appendix B: Dose Response Workshop
L. Rhomberg Presentation
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LCIA Needs for Assessing
Noncancer Effects
1. An approach to nonlinear dose-
response in humans
2. Estimates of the numbers of people














































Source: SJS Baird et al., SRA, 2000
Appendix B: Dose Response Workshop
L. Rhomberg Presentation
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Comparison of ED001h Distributions  for Fetal  Death for the









0 1000 2000 3000 4000
Dose (p p b )
Chun and Neeper-Bradley F0
Chun and Neeper-Bradley F1
Snellings F0
The challenge for exposure analysis:
to express the population distribution
of exposure
(per unit of emissions, without specific times
and places).




Source: Bennett, DH; McKone, TE; Kastenberg, WE. 2002. Characteristic time, characteristic travel distance, and
population-based potential dose in a multimedia environment: A case study. Human and Ecological Risk
Assessment: Theory and Practice (Ed.: Paustenbach, DJ). John Wiley & Sons, Inc.
Europe Population Density, 1995
Source: http://sedac.ciesin.columbia.edu/plue/gpw/europe.html






Source: The Lifeline Group
Appendix B: Dose Response Workshop
L. Rhomberg Presentation
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Thirty Five Year Olds











































Combining Risk and Exposure Distributions
